MOTS-c
Mitochondrial-Derived Peptide (16-amino acid)
A 16-amino-acid peptide encoded within the mitochondrial genome — one of the few peptides actually produced by mitochondria themselves. Drives AMPK activation, GLUT4 translocation, and mitochondrial biogenesis. The most-cited compound for amplifying GLP-1 fat-loss protocols by directly improving cellular energy metabolism.
Quick reference
How MOTS-c works
MOTS-c is a mitochondrial-derived peptide — encoded within the mitochondrial DNA's 12S rRNA region and translated by the cell. It's one of the few peptides produced by mitochondria themselves, which is why it acts as a mitochondrial-to-nuclear signal.
Primary mechanism: AMPK activation (the cellular energy sensor). AMPK activation drives GLUT4 translocation to muscle membranes (improving glucose uptake), increases fatty-acid oxidation, and promotes mitochondrial biogenesis through PGC-1α upregulation. This is the same pathway metformin hits, but MOTS-c is a more direct activator.
Why it stacks with GLP-1 agonists: Semaglutide and Tirzepatide drive weight loss via appetite suppression and improved insulin sensitivity. MOTS-c amplifies this by directly improving cellular energy metabolism — so the cells receiving the now-better insulin signal also have better mitochondrial substrate processing. Practitioner reports describe meaningful fat-loss acceleration when MOTS-c is added to a stable GLP-1 protocol.
In the DoseCraft framework, MOTS-c is the canonical compound for ATP Shortage (mitochondrial biogenesis + cellular fuel uptake) and Insulin Resistance (AMPK-driven GLUT4 translocation).
Reconstitution math
- Remove the flip-off cap from the 10 mg vial.
- Draw 1 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the vial wall.
- Swirl gently. Do not shake.
- Refrigerate. Stable approximately 4 weeks at 2–8°C.
Dose math
10 mg vial + 1 mL bac water → 10 mg per mL (10,000 mcg/mL).
On a 100-unit insulin syringe (1 IU = 0.01 mL):
- • 50 IU = 5 mg (5,000 mcg)
- • 100 IU = 10 mg (10,000 mcg)
- • Standard 5 mg dose = 50 IU (half mL)
Synergy stack
MOTS-c + Tirzepatide / Semaglutide — metabolic acceleration
GLP-1 agonists improve insulin signaling and reduce caloric intake. MOTS-c amplifies the downstream cellular response by directly activating AMPK and improving mitochondrial substrate processing. Practitioner reports describe meaningful fat-loss acceleration and better physique outcomes when MOTS-c is added to stable GLP-1 protocols.
MOTS-c protocol
5–10 mg per week TOTAL (split 2–3 injections)
Use case
Add after 8 weeks on stable GLP-1 dose
Safety + side-effect profile
Generally well-tolerated. Side-effect profile is mild and short-lived.
Not documented at standard doses: hepatotoxicity, hormonal disruption, significant cardiovascular changes. Contraindications: active cancer therapy (mitochondrial biogenesis is theoretically concerning in oncology), pregnancy, lactation, untreated severe diabetes (AMPK activation can trigger transient hypoglycemia in insulin-treated patients).
Interaction notes: stacks well with GLP-1 agonists, BPC-157, GHK-Cu. Caution with metformin (both hit AMPK; cumulative effect can be more potent than expected). Avoid concurrent use of multiple AMPK activators (berberine + metformin + MOTS-c) without practitioner supervision.
- • Mild post-injection warmth (transient, <30 minutes)
- • Occasional mild fatigue during first week of dosing
- • Transient mild hypoglycemia in insulin-sensitive users
- • Rare injection-site soreness
Frequently asked
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome — one of the few peptides actually produced by mitochondria themselves. Drives AMPK activation, GLUT4 translocation, and mitochondrial biogenesis. Used in metabolic and longevity protocols.
What is the typical MOTS-c dose?
Canonical foundational protocol: 5–10 mg subcutaneous per WEEK TOTAL, split across 2–3 injections (e.g. 3 mg Mon/Wed/Fri or 5 mg Mon/Fri). Inject fasted, before training — maximizes AMPK activation. Cycle: 8 weeks on / 4 weeks off. Older community descriptions of "5–10 mg 2–3× weekly" total 10–30 mg/week and are 3× higher than the canonical baseline; the consolidated total is per WEEK, not per injection.
How do I reconstitute MOTS-c?
10 mg vial + 1 mL bacteriostatic water → 10 mg/mL. On a 100-unit insulin syringe, 50 IU = 5 mg, 100 IU = full 10 mg. Refrigerate after reconstitution; stable approximately 4 weeks.
Why stack MOTS-c with GLP-1 agonists?
GLP-1 agonists (Semaglutide, Tirzepatide) drive weight loss via appetite suppression and improved insulin sensitivity. MOTS-c amplifies the downstream cellular response by activating AMPK and improving mitochondrial substrate processing. Adding MOTS-c after 8 weeks on a stable GLP-1 dose often accelerates fat loss by 20-40% in practitioner reports.
Is MOTS-c the same as metformin?
Mechanistically similar (both hit AMPK), but MOTS-c is a more direct activator and works at the mitochondrial level rather than upstream. Some practitioners use them together for additive effect; others view MOTS-c as a peptide-based metformin alternative for users who can't tolerate metformin's GI side effects.
Are there MOTS-c side effects?
Generally mild. Reported: post-injection warmth (transient), occasional mild fatigue first week, transient mild hypoglycemia in insulin-sensitive users, rare injection-site soreness. Not documented: hepatotoxicity, hormonal disruption, cardiovascular changes.
Should I cycle MOTS-c?
Yes. Standard cycling: 8-12 weeks on, 4 weeks off. Continuous use beyond 16 weeks is not better-supported in the literature than cycled use, and cycling allows endogenous mitochondrial regulation to remain responsive.
Will MOTS-c affect my bloodwork?
Possibly — most-tracked changes: improved fasting glucose, lower HbA1c (over 8-12 weeks), improved triglyceride / HDL ratio. Some users see mild ALT/AST elevation initially (reflects increased hepatic fat oxidation; typically normalizes). Re-test bloodwork at 8 weeks to confirm response.
Related compounds
Often researched, stacked, or compared with MOTS-c.
Cited research
Lee et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Reynolds et al. — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
Build your MOTS-c protocol with Coach
Coach personalizes the dose, stack, and cycle for your specific goals — and saves the result as a cited PDF you can bring to your doctor. Free for 14 days.
Start 14-Day Free TrialNo credit card · cancel anytime